Business Context and Reporting Period
Kodiak Sciences Inc. (Nasdaq: KOD) is a pre-commercial biotechnology company focused on developing transformative therapeutics for retinal diseases using its proprietary Antibody Biopolymer Conjugate (ABC) platform. The company has no approved products and has not generated product revenue since its inception in 2009. This filing covers the fiscal year ended December 31, 2025.
Key pipeline assets include:
- Zenkuda (tarcocimab): An anti-VEGF therapy for diabetic retinopathy (DR), retinal vein occlusion (RVO), and wet age-related macular degeneration (wet AMD). It has completed four successful Phase 3 studies (GLOW1, GLOW2, BEACON, DAYLIGHT) and is currently in the Phase 3 DAYBREAK study.
- KSI-501: A bispecific anti-IL-6/VEGF therapy in Phase 3 (DAYBREAK) for wet AMD.
- KSI-101: A bispecific protein for macular edema secondary to inflammation (MESI), currently in Phase 3 (PEAK and PINNACLE studies).
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(230.0) | $(176.2) |
| Research & Development Expenses | $182.4 | $126.1 |
| General & Administrative Expenses | $52.0 | $60.8 |
| Cash and Cash Equivalents (Year End) | $209.9 | $168.1 |
| Accumulated Deficit | $(1,558.7) | $(1,328.7) |
| Net Cash Used in Operating Activities | $(136.0) | $(117.3) |
Liquidity and Debt: The company had no debt as of December 31, 2025. It holds a liability of $100.0 million related to the sale of future royalties (capped at 4.5% of net sales of tarcocimab) to Baker Bros. Advisors, LP. The company raised $173.0 million in net proceeds from a public equity offering in December 2025.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by 31% to $230.0 million in 2025 compared to $176.2 million in 2024, driven primarily by higher R&D spending.
- R&D Expense Growth: R&D expenses rose 45% to $182.4 million. This was driven by increased costs for the tarcocimab program ($14.6M increase) and KSI-501/KSI-101 programs ($20.5M increase) due to the activation of the Phase 3 DAYBREAK trial and ongoing Phase 3 studies for KSI-101.
- G&A Reduction: General and administrative expenses decreased 14% to $52.0 million, largely due to lower stock-based compensation ($6.8M reduction) and reduced facility costs following the sublease of one Palo Alto building.
- Capital Raise: In December 2025, the company completed an equity offering of 8 million shares at $23.00 per share, netting $173.0 million, significantly bolstering cash reserves.
Guidance, Outlook, and Risks
Outlook and Milestones:
- BLA Submission: Kodiak intends to file a Biologics License Application (BLA) for tarcocimab in DR, RVO, and wet AMD in 2026.
- Data Readouts: Topline results for the Phase 3 DAYBREAK study (tarcocimab and KSI-501) are expected in Q3 2026. Topline data for KSI-101 Phase 3 studies (PEAK and PINNACLE) are expected in Q4 2026 and Q2 2027, respectively.
- Manufacturing: The company has commissioned the "Ursus" facility, a custom-built commercial-scale manufacturing site in collaboration with Lonza.
Going Concern Warning: Management has stated there is substantial doubt regarding the company's ability to continue as a going concern. Despite the recent capital raise, the company expects to continue incurring significant losses and negative operating cash flows. It anticipates needing additional capital to maintain operations and fund development.
Key Risks:
- Clinical Trial Failure: The company has previously failed to meet primary endpoints in the DAZZLE, GLEAM, and GLIMMER studies. Future success is not guaranteed.
- Regulatory Uncertainty: Approval of the ABC platform and specific dosing regimens (e.g., AI-driven dosing in DAYBREAK) is subject to FDA review.
- Competition: The retinal disease market is highly competitive with established therapies (e.g., Eylea, Vabysmo) and new entrants.
- Capital Requirements: Failure to secure additional financing could force the company to pause or discontinue development programs.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline management projects for current cash reserves ($209.9M) to support operations into 2027, given the "substantial doubt" disclosure.
- DAYBREAK Study Design: Review the specific AI-driven dosing criteria in the DAYBREAK trial and assess the likelihood of FDA acceptance for a flexible 1-6 month label.
- BLA Timing: Confirm the specific quarter in 2026 targeted for the tarcocimab BLA submission and whether it will include DAYBREAK data.
- Royalty Liability: Understand the terms of the $100M royalty liability to Baker Bros. Advisors, including the 4.5% cap and potential repurchase options.
- Manufacturing Capacity: Assess the readiness of the Ursus facility for commercial scale-up and any potential bottlenecks in supply chain for the ABC platform.